Abstract
Biopharmaceuticals have set new standards for blockbuster drugs recently. A blockbuster drug is the one which has crossed $1 billion or more in annual sales. Top 15 biopharma products have annual revenue more than $2 billion, and anti-inflammatory drugs like humira are generating $10 billion in revenue per year. These bioproducts are mostly large organic molecules like enzymes, hormones, clotting factors, monoclonal antibodies, and peptide therapeutics compared to a low-molecular-weight pharmaceutical product. Around 1500 biomolecules are undergoing clinical trials, and success rate of a biomolecule to pass a clinical test is twice as compared to pharma molecule. These promising outputs and low side effects of biopharmaceutical products are attracting major pharmaceutical companies, and they are slowly shifting their research and development and sourcing toward these large molecular bioproducts. These molecules are produced mostly inside a bioreactor with upstream and downstream processes, and the effluent contents of these industries are a matter of concern because they contain various unorthodox organic components, i.e., recombinant fermentation broth, extremophiles, bacterial spores, and various antibiotics. The absence of an effective treatment methodology with various bio-industries to deal with this modern organic recombinant sludge is the major reason behind the increase in a number of untreatable superbugs in our ecosystem. There is an urgent need to improve the traditional primary, secondary, and tertiary modes of wastewater treatment methodology to handle this new threat. This chapter provides an insight knowledge to traditional and modern methods implemented for effluent treatment for biopharmaceutical effluents and an advancement of treatment technologies like MODAR supercritical water oxidation, membrane biological reactor (MBR) technology, reverse osmosis technology, ozonation plant technology, and modular thermal plant treatment for effective treatment of biopharma effluent streams to achieve zero contaminant discharge strategy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adishkumar S, Sivajothi S, Rajesh Banu J (2012) Coupled solar photo-Fenton process with aerobic sequential batch reactor for treatment of pharmaceutical wastewater. Desalin Water Treat 48:89–95. https://doi.org/10.1080/19443994.2012.698799
Al-Farsi R, Ahmed M, Al-Busaidi A, Choudri BS (2018) Assessing the presence of pharmaceuticals in soil and plants irrigated with treated wastewater in Oman. Int J Recycl Org Waste Agric 7:165–172. https://doi.org/10.1007/s40093-018-0202-1
Arnold KE, Brown AR, Brown AR, Ankley GT, Sumpter JP (2014) Medicating the environment: assessing risks of pharmaceuticals to wildlife and ecosystems. Philos Trans R Soc B Biol Sci 369:20130569. https://doi.org/10.1098/rstb.2013.0569
Arya V, Philip L, Murty Bhallamudi S (2016) Performance of suspended and attached growth bioreactors for the removal of cationic and anionic pharmaceuticals. Chem Eng J 284:1295–1307. https://doi.org/10.1016/j.cej.2015.09.070
Atun RA, Gurol-urganci I, Sheridan D (2007) Uptake and diffusion of pharmaceutical innovations in health systems. Int J Innov Manag 11:299–321. https://doi.org/10.1142/s1363919607001709
Bernhard M, Müller J, Knepper TP (2006) Biodegradation of persistent polar pollutants in wastewater: comparison of an optimised lab-scale membrane bioreactor and activated sludge treatment. Water Res 40:3419–3428. https://doi.org/10.1016/j.watres.2006.07.011
Boroski M, Rodrigues AC, Garcia JC, Sampaio LC, Nozaki J, Hioka N (2009) Combined electrocoagulation and TiO2 photoassisted treatment applied to wastewater effluents from pharmaceutical and cosmetic industries. J Hazard Mater 162:448–454. https://doi.org/10.1016/j.jhazmat.2008.05.062
Clara M, Kreuzinger N, Strenn B, Gans O, Kroiss H (2005) The solids retention time—a suitable design parameter to evaluate the capacity of wastewater treatment plants to remove micropollutants. Water Res 39:97–106. https://doi.org/10.1016/j.watres.2004.08.036
Crane M, Watts C, Boucard T (2006) Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ 367:23–41. https://doi.org/10.1016/j.scitotenv.2006.04.010
Csefalvay E, Koczka K, Mizsey P (2007) Treatment of pharmaceutical waste water by hybrid separation processes. In: Proceedings of European Congress of Chemical Engineering (ECCE-6) Copenhagen, pp 1–4
Das MP, Bashwant M, Kumar K, Das J (2012) Control of pharmaceutical effluent parameters through bioremediation. J Chem Pharm Res 4:1061–1065
De Gusseme B, Pycke B, Hennebel T, Marcoen A, Vlaeminck SE, Noppe H, Boon N, Verstraete W (2009) Biological removal of 17α-ethinylestradiol by a nitrifier enrichment culture in a membrane bioreactor. Water Res 43:2493–2503. https://doi.org/10.1016/j.watres.2009.02.028
D ȩbska J, Kot-Wasik A, Namieśnik J (2004) Fate and analysis of pharmaceutical residues in the aquatic environment. Crit Rev Anal Chem 34:51–67. https://doi.org/10.1080/10408340490273753
Deegan AM, Shaik B, Nolan K, Urell K, Oelgemöller M, Tobin J, Morrissey A (2011) Treatment options for wastewater effluents from pharmaceutical companies. Int J Environ Sci Technol 8:649–666. https://doi.org/10.1007/BF03326250
Duca G, Boldescu V (2009) Pharmaceuticals and personal care products in the. Environment 28:27–35. https://doi.org/10.1007/978-90-481-2903-4_3
Gadipelly C, Rathod VK, Marathe KV (2014) Pharmaceutical industry wastewater: review of the technologies for water treatment. Ind Eng Chem Res 53(29):11571–11592. https://doi.org/10.1021/ie501210j
Gkotsis P, Banti D, Peleka E, Zouboulis A, Samaras P (2014) Fouling issues in membrane bioreactors (MBRs) for wastewater treatment: major mechanisms, prevention and control strategies. PRO 2:795–866. https://doi.org/10.3390/pr2040795
Göbel A, Thomsen A, McArdell CS, Joss A, Giger W (2005) Occurrence and sorption behavior of sulfonamides, macrolides, and trimethoprim in activated sludge treatment. Environ Sci Technol 39:3981–3989. https://doi.org/10.1021/es048550a
Gomes J, Costa R, Quinta-Ferreira RM, Martins RC (2017) Application of ozonation for pharmaceuticals and personal care products removal from water. Sci Total Environ 586:265–283. https://doi.org/10.1016/j.scitotenv.2017.01.216
Grandclément C, Seyssiecq I, Piram A, Wong-Wah-Chung P, Vanot G, Tiliacos N, Roche N, Doumenq P (2017) From the conventional biological wastewater treatment to hybrid processes, the evaluation of organic micropollutant removal: a review. Water Res 111:297–317. https://doi.org/10.1016/j.watres.2017.01.005
Gros M, Petrović M, Ginebreda A, Barceló D (2010) Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 36:15–26. https://doi.org/10.1016/j.envint.2009.09.002
Huang L, Lee DJ (2015) Membrane bioreactor: a mini review on recent R&D works. Bioresour Technol 194:383–388. https://doi.org/10.1016/j.biortech.2015.07.013
Iorhemen OT, Hamza RA, Tay JH (2016) Membrane bioreactor (Mbr) technology for wastewater treatment and reclamation: membrane fouling. Membranes (Basel) 6:13–16. https://doi.org/10.3390/membranes6020033
Joss A, Andersen H, Ternes T, Richle PR, Siegrist H (2004) Removal of estrogens in municipal wastewater treatment under aerobic and anaerobic conditions: consequences for plant optimization. Environ Sci Technol 38:3047–3055. https://doi.org/10.1021/es0351488
Khetan SK, Collins TJ (2007) Human pharmaceuticals in the aquatic environment a review. Environ Technol 22:1383–1394. https://doi.org/10.1080/09593332208618186
Kimura K, Hara H, Watanabe Y (2005) Removal of pharmaceutical compounds by submerged membrane bioreactors (MBRs). Desalination 178:135–140. https://doi.org/10.1016/j.desal.2004.11.033
Klavarioti M, Mantzavinos D, Kassinos D (2009) Removal of residual pharmaceuticals from aqueous systems by advanced oxidation processes. Environ Int 35:402–417. https://doi.org/10.1016/j.envint.2008.07.009
Krzeminski P, Tomei MC, Karaolia P, Langenhoff A, Almeida CMR, Felis E, Gritten F, Andersen HR, Fernandes T, Manaia CM, Rizzo L, Fatta-Kassinos D (2019) Performance of secondary wastewater treatment methods for the removal of contaminants of emerging concern implicated in crop uptake and antibiotic resistance spread: a review. Sci Total Environ 648:1052–1081. https://doi.org/10.1016/j.scitotenv.2018.08.130
Lacey C, Basha S, Morrissey A, Tobin JM (2012) Occurrence of pharmaceutical compounds in wastewater process streams in Dublin, Ireland. Environ Monit Assess 184:1049–1062. https://doi.org/10.1007/s10661-011-2020-z
Larsson DGJ (2014) Pollution from drug manufacturing: review and perspectives. Philos Trans R Soc Lond B Biol Sci 369:20130571. https://doi.org/10.1098/rstb.2013.0571
Mantzavinos D, Psillakis E (2004) Enhancement of biodegradability of industrial wastewaters by chemical oxidation pre-treatment. J Chem Technol Biotechnol 79:431–454. https://doi.org/10.1002/jctb.1020
Marketresearch.com (2018) The growing pharmaceuticals market: expert forecasts and analysis, pp 1–13
Miron AR, Chivu A-MA, Rikabi AAKK, Albu PC (2014) Pharmaceutical industry wastewater treatment through electrocoagulation. Rev Chim 65:1399–1406
Oller I, Malato S, Sánchez-Pérez JA (2011) Combination of advanced oxidation processes and biological treatments for wastewater decontamination—a review. Sci Total Environ 409:4141–4166. https://doi.org/10.1016/j.scitotenv.2010.08.061
Pomati F, Castiglioni S, Zuccato E, Fanelli R, Vigetti D, Rossetti C, Calamari D (2006) Effects of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells. Environ Sci Technol 40:2442–2447. https://doi.org/10.1021/es051715a
Quinn B, Gagné F, Blaise C (2008) An investigation into the acute and chronic toxicity of eleven pharmaceuticals (and their solvents) found in wastewater effluent on the cnidarian, Hydra attenuata. Sci Total Environ 389:306–314. https://doi.org/10.1016/j.scitotenv.2007.08.038
Radjenović J, Petrović M, Barceló D (2009) Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. Water Res 43:831–841. https://doi.org/10.1016/j.watres.2008.11.043
Shariati FP, Mehrnia MR, Salmasi BM, Heran M, Wisniewski C, Sarrafzadeh MH (2010) Membrane bioreactor for treatment of pharmaceutical wastewater containing acetaminophen. Desalination 250:798–800. https://doi.org/10.1016/j.desal.2008.11.044
Sipma J, Osuna B, Collado N, Monclús H, Ferrero G, Comas J, Rodriguez-Roda I (2010) Comparison of removal of pharmaceuticals in MBR and activated sludge systems. Desalination 250:653–659. https://doi.org/10.1016/j.desal.2009.06.073
Snyder SA, Adham S, Redding AM, Cannon FS, DeCarolis J, Oppenheimer J, Wert EC, Yoon Y (2007) Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals. Desalination 202:156–181. https://doi.org/10.1016/j.desal.2005.12.052
Tiwari B, Sellamuthu B, Ouarda Y, Drogui P, Tyagi RD, Buelna G (2017) Review on fate and mechanism of removal of pharmaceutical pollutants from wastewater using biological approach. Bioresour Technol 224:1–12. https://doi.org/10.1016/j.biortech.2016.11.042
Van Lier JB, Mahmoud N, Zeeman G (2008) Biological wastewater treatment: principles, moddeling and design—Chapter 16: anaerobic wastewater treatment
Wang Y, Wang X, Li M, Dong J, Sun C, Chen G (2018) Removal of pharmaceutical and personal care products (PPCPs) from municipalwaste water with integrated membrane systems, MBR-RO/NF. Int J Environ Res Public Health 15. https://doi.org/10.3390/ijerph15020269
Wei X, Li B, Zhao S, Wang L, Zhang H, Li C, Wang S (2012) Mixed pharmaceutical wastewater treatment by integrated membrane-aerated biofilm reactor (MABR) system—a pilot-scale study. Bioresour Technol 122:189–195. https://doi.org/10.1016/j.biortech.2012.06.041
Wen X, Ding H, Huang X, Liu R (2004) Treatment of hospital wastewater using a submerged membrane bioreactor. Process Biochem 39:1427–1431. https://doi.org/10.1016/S0032-9592(03)00277-2
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Acharya, D., Satapathy, S., Tapas Kumar Dora, D., Dave, S., Das, J. (2020). Advancement in Treatment Technologies of Biopharmaceutical Industrial Effluents. In: Shah, M. (eds) Microbial Bioremediation & Biodegradation. Springer, Singapore. https://doi.org/10.1007/978-981-15-1812-6_18
Download citation
DOI: https://doi.org/10.1007/978-981-15-1812-6_18
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-1811-9
Online ISBN: 978-981-15-1812-6
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)